We are live on ! Find out more
NM

Newtyn Management Portfolio holdings

AUM $936M
1-Year Est. Return 27.23%
This Fund
S&P 500
This Quarter Est. Return
-9.54%
1 Year Est. Return
+27.23%
3 Year Est. Return
+51.99%
5 Year Est. Return
+55.23%
10 Year Est. Return
+165.15%
AUM
$455M
AUM Growth
-$72.3M
Cap. Flow
-$12.5M
Cap. Flow %
-2.74%
Top 10 Hldgs %
51.9%
Holding
94
New
10
Increased
20
Reduced
27
Closed
14

Top Buys

Rank Stock Value
1
SLVM icon
Sylvamo
SLVM
+$16.7M
2
SAFE
Safehold
SAFE
+$12.1M
3
PPLI
People Inc
PPLI
+$6.86M
4
ILPT
Industrial Logistics Properties Trust
ILPT
+$4.52M
5
FLWS icon
1-800-Flowers.com
FLWS
+$4.48M

Top Sells

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$11.1M
2
ASTL icon
Algoma Steel
ASTL
+$8.12M
3
LQDA icon
Liquidia Corp
LQDA
+$6.84M
4
TSVT
2seventy bio
TSVT
+$5.89M
5
RDUS
Radius Health, Inc.
RDUS
+$3.96M

Sector Composition

Rank Sector Weight
1 Healthcare 20.49%
2 Consumer Discretionary 19.55%
3 Financials 13.18%
4 Real Estate 9.6%
5 Technology 6.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCRR
51
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$1.08M 0.24%
600,000
-92,799
-13% -$269K
DBTX
52
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$1.04M 0.23%
300,000
-10,000
-3% -$45.5K
ORKA
53
Oruka Therapeutics
ORKA
$5.82B
$1.03M 0.23%
+41,667
New +$1.18M
IOVA icon
54
Iovance Biotherapeutics
IOVA
$1.82B
$1.01M 0.22%
105,000
– –
ALEC icon
55
Alector
ALEC
$168M
$993K 0.22%
105,000
– –
LTCH
56
DELISTED
Latch, Inc. Common Stock
LTCH
$954K 0.21%
1,000,000
-500,000
-33% -$573K
BOLT icon
57
Bolt Biotherapeutics
BOLT
$7.67M
$888K 0.2%
30,000
-7,413
-20% -$307K
AMR icon
58
Alpha Metallurgical Resources
AMR
$1.74B
$865K 0.19%
6,319
– –
ADVM
59
DELISTED
Adverum Biotechnologies
ADVM
$855K 0.19%
90,000
-13,500
-13% -$177K
WGS icon
60
GeneDx Holdings
WGS
$1.93B
$790K 0.17%
27,273
-7,424
-21% -$340K
FTH
61
Faeth Therapeutics
FTH
$702M
$643K 0.14%
20,750
– –
TCRX icon
62
TScan Therapeutics
TCRX
$48.6M
$610K 0.13%
200,000
-48,611
-20% -$159K
BDTX icon
63
Black Diamond Therapeutics
BDTX
$96.8M
$592K 0.13%
350,000
-170,000
-33% -$524K
FBRX icon
64
Forte Biosciences
FBRX
$1.57B
$535K 0.12%
+20,000
New +$635K
NUVB icon
65
Nuvation Bio
NUVB
$2.2B
$470K 0.1%
210,000
– –
SIOX
66
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$420K 0.09%
1,500,000
+84,141
+6% +$28.8K
ORIC icon
67
Oric Pharmaceuticals
ORIC
$1.15B
$400K 0.09%
125,000
-25,000
-17% -$100K
PASG icon
68
Passage Bio
PASG
$14.4M
$375K 0.08%
15,000
-16,000
-52% -$631K
LAXXR
69
DELISTED
8i Acquisition 2 Corp Rights
LAXXR
$351K 0.08%
750,000
– –
IOBT
70
DELISTED
IO Biotech
IOBT
$271K 0.06%
+100,000
New +$371K
GBTG.WS
71
DELISTED
Global Business Travel Group, Inc. Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
GBTG.WS
$187K 0.04%
+118,828
New +$156K
LFLYW
72
DELISTED
Leafly Holdings, Inc. Warrant
LFLYW
$108K 0.02%
+634,640
New +$240K
AGBAR
73
DELISTED
AGBA Acquisition Ltd Right
AGBAR
$69K 0.02%
500,000
– –
BRLIR
74
DELISTED
Brilliant Acquisition Corporation Rights
BRLIR
$63K 0.01%
457,409
– –
BENER
75
DELISTED
Benessere Capital Acquisition Corp. Right
BENER
$34K 0.01%
250,000
– –
1 2
3
4

Similar funds

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return
FPI
Financial Plan Inc Bellingham, Washington $933M AUM

Newtyn Management's Q3 2022 Portfolio in Review

As of Q3 2022, Newtyn Management held 94 positions worth $455M, down 14% from $528M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Newtyn Management's Q3 2022 filing shows 10 new, 20 increased, 27 reduced and 14 closed positions. Its largest new stake was Sylvamo: 438,674 shares worth $14.9M. The largest sale was Epizyme, Inc, an estimated $11.1M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 23% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Newtyn Management's largest Q3 2022 buy was Sylvamo: 438,674 shares worth $14.9M.
  • Newtyn Management added most to People Inc in Q3 2022, an estimated $6.86M increase.
  • Newtyn Management's biggest Q3 2022 reduction was Algoma Steel, cutting an estimated $8.12M.
  • Newtyn Management fully exited Epizyme, Inc in Q3 2022, selling an estimated $11.1M.
  • Newtyn Management's ten largest holdings make up 52% of its $455M portfolio in Q3 2022.
  • Newtyn Management opened 10 new positions and closed 14 in Q3 2022.
  • Newtyn Management's portfolio value fell 14% quarter-over-quarter to $455M.

Based on Newtyn Management's 13F filing for Q3 2022, filed 14 Nov 2022.